It is with great satisfaction and pride that we announce that the first patient in the country to start an innovative treatment for breast cancer did it with us. In addition to this, we also started immunotherapy associated with chemotherapy in gastric cancer.
The HPA Oncology Unit continues its path of excellence in the care of cancer patients, striving for the integration of the most innovative treatments, highlights the oncologist André Andraz Cruz.
Indeed, the first patient in Portugal started treatment with Phesgo - Trastuzumab + Pertuzumab, indicated for HER2 + breast cancer (early and metastatic). These drugs already existed but were administered separately intravenously. With this new formulation for subcutaneous administration - validated in the “FeDeriCa” and “PHranceSCa” studies - in addition to the comparable results in decreasing the risk of disease recurrence, resources are optimised and above all, it provides greater comfort and quality of life for the patient.
Also undergoing treatment with us is one of the first patients at the national level to undergo immunotherapy (Nivolumab) associated with chemotherapy for advanced gastric cancer. This strategy was recently validated by the European Medicines Agency (phase 3 study Checkmate 649) which aims to improve the survival in a reserved prognosis pathology, thus constituting a potential “standard of care”, says Dr. André Andraz Cruz.
12th April 202112, April 2021